Plus Therapeutics (PSTV) Non-Current Assets (2010 - 2026)

Plus Therapeutics (PSTV) has 17 years of Non-Current Assets data on file, last reported at $1.9 million in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $1.9 million, up 58.92% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.3 million (down 12.4% YoY), and the FY2025 annual result was $1.2 million, down 15.94% from the prior year.
• Non-Current Assets rose to $1.9 million in Q1 2026 per PSTV's latest filing, from $1.2 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $2.4 million in Q1 2022 and troughed at $1.1 million in Q3 2025.
• A 5-year average of $1.7 million and a median of $1.7 million in 2023 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2025 and 2026: Non-Current Assets plunged 37.99% in 2025, then soared 58.92% in 2026.
• A 5-year view of Non-Current Assets shows it stood at $2.0 million in 2022, then dropped by 24.2% to $1.6 million in 2023, then retreated by 11.58% to $1.4 million in 2024, then retreated by 15.94% to $1.2 million in 2025, then jumped by 63.46% to $1.9 million in 2026.
• Business Quant data shows PSTV's Non-Current Assets at $1.9 million in Q1 2026, $1.2 million in Q4 2025, and $1.1 million in Q3 2025.